Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVV001 in Severe Hemophilia A (XTEND-ed)
NCT04644575Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Feb 2021
- Primary completion
- Jan 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 23
01
Overview
A Phase 3 trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Started Feb 2021; status: active, not recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04644575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644575.